Prosensa wins “Emerging Star Award” at the European Mediscience Awards

Leiden, The Netherlands, 22 June 2012 – Prosensa, the Dutch bio­phar­ma­ceu­ti­cal com­pa­ny focus­ing on rare dis­eases with a high unmet med­ical need, has won the Emerging Star acco­lade at last night’s European Mediscience Awards.

The European Mediscience Awards is the largest annu­al gath­er­ing of pri­vate and pub­licly quot­ed health­care, biotech and life sci­ence com­pa­nies in Europe recog­nis­ing achieve­ments in the life sci­ences indus­try. Supported by Peel Hunt, the inau­gur­al Emerging Star Award cel­e­brates the achieve­ments of a pri­vate or young pub­lic medi­science com­pa­ny that has demon­stra­ble cred­i­bil­i­ty in terms of busi­ness model/strategy, man­age­ment team and financ­ing. The winner’s focus on inno­va­tion is also key, with its technology/IP capa­ble of sig­nif­i­cant mar­ket impact or dis­rup­tion.
Collecting the award, Dr.Giles Campion, Prosensa’s Chief Medical Officer and SVP Research & Development said: “We are very pleased to be recog­nised by the European Mediscience judg­ing pan­el. This pres­ti­gious award is an addi­tion­al moti­va­tion in our efforts to help patients and their fam­i­lies affect­ed by rare, pro­gres­sive­ly debil­i­tat­ing dis­eases.”

Prosensa has the most advanced port­fo­lio of drug can­di­dates for the treat­ment of Duchenne mus­cu­lar dys­tro­phy (DMD), with two com­pounds in clin­i­cal tri­als in part­ner­ship with GlaxoSmithKline and four addi­tion­al com­pounds in late stage pre-clin­i­cal devel­op­ment. Prosensa’s DMD com­pounds are based on its pro­pri­etary exon-skip­ping tech­nol­o­gy that uses anti­sense oligonu­cleotides to restore expres­sion of a func­tion­al dys­trophin pro­tein and to pro­vide poten­tial treat­ment for patients affect­ed by this pro­gres­sive­ly debil­i­tat­ing neu­ro­mus­cu­lar dis­ease. The com­pa­ny recent­ly raised €23 mil­lion in a pri­vate equi­ty financ­ing round and is sup­port­ed by a con­sor­tium of investors includ­ing Abingworth, Gimv, Idinvest Partners, Life Sciences Partners, MedSciences Capital and New Enterprise Associates. The oth­er com­pa­nies short­list­ed for the Mediscience “Emerging Star Award” were BioCartis NV, Oxford Nanopore Technologies Ltd and Sphere Medical Ltd.

Leave a Reply

Your email address will not be published. Required fields are marked *